Search Media Items

Hoja informativa que resume la evidencia disponible acerca del uso de los teléfonos celulares y el riesgo de cáncer.

A summary of clinical trial results showing that nivolumab (Opdivo®) improved overall survival compared with standard chemotherapy in patients with head and neck squamous cell carcinoma.

Resumen de información revisada por expertos sobre el uso del régimen Gonzalez como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.

Resumen de información revisada por expertos sobre el uso de cartílago bovino y de tiburón como tratamiento para personas con cáncer. Nota: la información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.

Immunotherapy is treatment that helps your immune system fight cancer. Get information about the different types of immunotherapy and what you can expect during treatment.

Information to help people evaluate the source and credibility of health information that they find in print or online.

Read about how NCI is working to reduce cancer disparities by bringing clinical trials to minority and underserved communities.

Medicamento experimental es el evaluado en laboratorios y en animales y aprobado por la FDA de EE. UU. para probarse en personas, pero no puede anunciarse, venderse o recetarse. Medicamentos experimentales pueden estar disponibles por estudios clínicos o por programas de extensión de acceso. Aprenda más.

Human tumor atlases act as maps that describe the multidimensional cellular, structural, and molecular characteristics of human cancers over time. This information will improve understanding of how cancers develop and respond to treatment, ultimately improving care.

Despite significant progress in the treatment of breast cancer, the transition of pre-invasive ductal carcinoma in situ (DCIS) to more aggressive invasive ductal carcinoma (IDC) remains unknown. No prognostic biomarkers can reliably predict the risk of progression from DCIS to IDC. Similar genomic profiles of matched pre-invasive DCIS and IDC suggests that the progression is not driven by genetic aberrations in DCIS cells, but microenvironmental factors, such as hypoxia and metabolic stress prevalent in DCIS, may drive the transition.